The anti-papillomavirus activity of human and bovine lactoferricin

Antiviral Research

Volumn 75, Issue 3, 2007, Pages 258-265

  Mistry, Nitesh ^a   Drobni, Peter ^a   Näslund, Jonas ^a   Sunkari, Vivekananda Gupta ^a   Jenssen, Håvard ^b   Evander, Magnus ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

Antiviral activity; Human papillomavirus; Lactoferricin; Lactoferrin

Indexed keywords

LACTOFERRICIN; LACTOFERRIN;

ANTIVIRAL ACTIVITY; ARTICLE; CELL LINE; CONTROLLED STUDY; DRUG INHIBITION; EPITHELIUM CELL; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; NONHUMAN; PRIORITY JOURNAL; VIRUS INFECTION;

ANIMALS; ANTIVIRAL AGENTS; BETAPAPILLOMAVIRUS; CATTLE; CELL LINE; HUMAN PAPILLOMAVIRUS 16; HUMANS; LACTOFERRIN; PEPTIDES; VIRUS INTERNALIZATION;

BOVINAE; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; PAPILLOMAVIRIDAE;

EID: 34250211795     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2007.03.012     Document Type: Article

References (78)

1. Ammendolia M.G., Pietrantoni A., Tinari A., Valenti P., and Superti F. Bovine lactoferrin inhibits echovirus endocytic pathway by interacting with viral structural polypeptides. Antiviral Res. 73 3 (2007) 151-160
2. Andersen J.H., Osbakk S.A., Vorland L.H., Traavik T., and Gutteberg T.J. Lactoferrin and cyclic lactoferricin inhibit the entry of human cytomegalovirus into human fibroblasts. Antiviral Res. 51 2 (2001) 141-149
3. Andersen J.H., Jenssen H., and Gutteberg T.J. Lactoferrin and lactoferricin inhibit Herpes simplex 1 and 2 infection and exhibit synergy when combined with acyclovir. Antiviral Res. 58 3 (2003) 209-215
4. Andersen J.H., Jenssen H., Sandvik K., and Gutteberg T.J. Anti-HSV activity of lactoferrin and lactoferricin is dependent on the presence of heparan sulphate at the cell surface. J. Med. Virol. 74 2 (2004) 262-271
5. Antonsson A., Erfurt C., Hazard K., Holmgren V., Simon M., Kataoka A., Hossain S., Hakangard C., and Hansson B.G. Prevalence and type spectrum of human papillomaviruses in healthy skin samples collected in three continents. J. Gen. Virol. 84 Pt 7 (2003) 1881-1886
6. Bard E., Riethmuller D., Meillet D., Pretet J.L., Schaal J.P., Mougin C., and Seilles E. High-risk papillomavirus infection is associated with altered antibody responses in genital tract: non-specific responses in HPV infection. Viral Immunol. 17 3 (2004) 381-389
7. Bellamy W., Takase M., Wakabayashi H., Kawase K., and Tomita M. Antibacterial spectrum of lactoferricin B, a potent bactericidal peptide derived from the N-terminal region of bovine lactoferrin. J. Appl. Bacteriol. 73 6 (1992) 472-479
8. Bellamy W., Takase M., Yamauchi K., Wakabayashi H., Kawase K., and Tomita M. Identification of the bactericidal domain of lactoferrin. Biochim. Biophys. Acta 1121 1-2 (1992) 130-136
9. Bellamy W.R., Wakabayashi H., Takase M., Kawase K., Shimamura S., and Tomita M. Role of cell-binding in the antibacterial mechanism of lactoferricin B. J. Appl. Bacteriol. 75 5 (1993) 478-484
10. Berkhout R.J., Tieben L.M., Smits H.L., Bavinck J.N., Vermeer B.J., and ter Schegget J. Nested PCR approach for detection and typing of epidermodysplasia verruciformis-associated human papillomavirus types in cutaneous cancers from renal transplant recipients. J. Clin. Microbiol. 33 3 (1995) 690-695
11. Berkhout B., van Wamel J.L., Beljaars L., Meijer D.K., Visser S., and Floris R. Characterization of the anti-HIV effects of native lactoferrin and other milk proteins and protein-derived peptides. Antiviral Res. 55 2 (2002) 341-355
12. Boukamp P., Petrussevska R.T., Breitkreutz D., Hornung J., Markham A., and Fusenig N.E. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J. Cell Biol. 106 3 (1988) 761-771
13. Bousarghin L., Touze A., Yvonnet B., and Coursaget P. Positively charged synthetic peptides from structural proteins of papillomaviruses abrogate human papillomavirus infectivity. J. Med. Virol. 73 3 (2004) 474-480
14. Britigan B.E., Hayek M.B., Doebbeling B.N., and Fick Jr. R.B. Transferrin and lactoferrin undergo proteolytic cleavage in the Pseudomonas aeruginosa-infected lungs of patients with cystic fibrosis. Infect. Immun. 61 12 (1993) 5049-5055
15. Buck C.B., Pastrana D.V., Lowy D.R., and Schiller J.T. Efficient intracellular assembly of papillomaviral vectors. J. Virol. 78 2 (2004) 751-757
16. Buck C.B., Pastrana D.V., Lowy D.R., and Schiller J.T. Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol. Med. 119 (2005) 445-462
17. Buck C.B., Day P.M., Thompson C.D., Lubkowski J., Lu W., Lowy D.R., and Schiller J.T. Human alpha-defensins block papillomavirus infection. Proc. Natl. Acad. Sci. U.S.A. 103 5 (2006) 1516-1521
18. Buck C.B., Thompson C.D., Roberts J.N., Muller M., Lowy D.R., and Schiller J.T. Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog. 2 7 (2006) e69
19. Christensen N.D., Reed C.A., Culp T.D., Hermonat P.L., Howett M.K., Anderson R.A., and Zaneveld L.J. Papillomavirus microbicidal activities of high-molecular-weight cellulose sulfate, dextran sulfate, and polystyrene sulfonate. Antimicrob. Agents Chemother. 45 12 (2001) 3427-3432
20. Cohen M.S., Britigan B.E., French M., and Bean K. Preliminary observations on lactoferrin secretion in human vaginal mucus: variation during the menstrual cycle, evidence of hormonal regulation, and implications for infection with Neisseria gonorrhoeae. Am. J. Obstet. Gynecol. 157 5 (1987) 1122-1125
21. Combita A.L., Touze A., Bousarghin L., Sizaret P.Y., Munoz N., and Coursaget P. Gene transfer using human papillomavirus pseudovirions varies according to virus genotype and requires cell surface heparan sulfate. FEMS Microbiol. Lett. 204 1 (2001) 183-188
22. Crook T., Wrede D., and Vousden K.H. p53 point mutation in HPV negative human cervical carcinoma cell lines. Oncogene 6 5 (1991) 873-875
23. Day P.M., Baker C.C., Lowy D.R., and Schiller J.T. Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression. Proc. Natl. Acad. Sci. U.S.A. 101 39 (2004) 14252-14257
24. de Villiers E.M., Fauquet C., Broker T.R., Bernard H.U., and zur Hausen H. Classification of papillomaviruses. Virology 324 1 (2004) 17-27
25. Di Biase A.M., Pietrantoni A., Tinari A., Siciliano R., Valenti P., Antonini G., Seganti L., and Superti F. Heparin-interacting sites of bovine lactoferrin are involved in anti-adenovirus activity. J. Med. Virol. 69 4 (2003) 495-502
26. Dionysius D.A., and Milne J.M. Antibacterial peptides of bovine lactoferrin: purification and characterization. J. Dairy Sci. 80 4 (1997) 667-674
27. Drobni P., Mistry N., McMillan N., and Evander M. Carboxy-fluorescein diacetate, succinimidyl ester labeled papillomavirus virus-like particles fluoresce after internalization and interact with heparan sulfate for binding and entry. Virology 310 1 (2003) 163-172
28. Drobni P., Naslund J., and Evander M. Lactoferrin inhibits human papillomavirus binding and uptake in vitro. Antiviral Res. 64 1 (2004) 63-68
29. Eliassen L.T., Berge G., Sveinbjornsson B., Svendsen J.S., Vorland L.H., and Rekdal O. Evidence for a direct antitumor mechanism of action of bovine lactoferricin. Anticancer Res. 22 5 (2002) 2703-2710
30. Epand R.M., and Vogel H.J. Diversity of antimicrobial peptides and their mechanisms of action. Biochim. Biophys. Acta 1462 1-2 (1999) 11-28
31. Evander M., Frazer I.H., Payne E., Qi Y.M., Hengst K., and McMillan N.A. Identification of the alpha 6 integrin as a candidate receptor for papillomaviruses. J. Virol. 71 3 (1997) 2449-2456
32. Farley J., Loup D., Nelson M., Mitchell A., Esplund G., Macri C., Harrison C., and Gray K. Neoplastic transformation of the endocervix associated with downregulation of lactoferrin expression. Mol. Carcinog. 20 2 (1997) 240-250
33. Gifford J.L., Hunter H.N., and Vogel H.J. Lactoferricin: a lactoferrin-derived peptide with antimicrobial, antiviral, antitumor and immunological properties. Cell. Mol. Life Sci. 62 22 (2005) 2588-2598
34. Giroglou T., Florin L., Schafer F., Streeck R.E., and Sapp M. Human papillomavirus infection requires cell surface heparan sulfate. J. Virol. 75 3 (2001) 1565-1570
35. Hara K., Ikeda M., Saito S., Matsumoto S., Numata K., Kato N., Tanaka K., and Sekihara H. Lactoferrin inhibits hepatitis B virus infection in cultured human hepatocytes. Hepatol. Res. 24 3 (2002) 228
36. Harmsen M.C., Swart P.J., de Bethune M.P., Pauwels R., De Clercq E., The T.H., and Meijer D.K. Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro. J. Infect. Dis. 172 2 (1995) 380-388
37. Hasegawa K., Motsuchi W., Tanaka S., and Dosako S. Inhibition with lactoferrin of in vitro infection with human herpes virus. Jpn. J. Med. Sci. Biol. 47 2 (1994) 73-85
38. Haversen L.A., Engberg I., Baltzer L., Dolphin G., Hanson L.A., and Mattsby-Baltzer I. Human lactoferrin and peptides derived from a surface-exposed helical region reduce experimental Escherichia coli urinary tract infection in mice. Infect. Immun. 68 10 (2000) 5816-5823
39. He J., and Furmanski P. Sequence specificity and transcriptional activation in the binding of lactoferrin to DNA. Nature 373 6516 (1995) 721-724
40. Hendrixson D.R., Qiu J., Shewry S.C., Fink D.L., Petty S., Baker E.N., Plaut A.G., and St Geme III J.W. Human milk lactoferrin is a serine protease that cleaves Haemophilus surface proteins at arginine-rich sites. Mol. Microbiol. 47 3 (2003) 607-617
41. Hunter H.N., Demcoe A.R., Jenssen H., Gutteberg T.J., and Vogel H.J. Human lactoferricin is partially folded in aqueous solution and is better stabilized in a membrane mimetic solvent. Antimicrob. Agents Chemother. 49 8 (2005) 3387-3395
42. Hwang P.M., Zhou N., Shan X., Arrowsmith C.H., and Vogel H.J. Three-dimensional solution structure of lactoferricin B, an antimicrobial peptide derived from bovine lactoferrin. Biochemistry 37 12 (1998) 4288-4298
43. Ikeda M., Sugiyama K., Tanaka T., Tanaka K., Sekihara H., Shimotohno K., and Kato N. Lactoferrin markedly inhibits hepatitis C virus infection in cultured human hepatocytes. Biochem. Biophys. Res. Commun. 245 2 (1998) 549-553
44. Ikeda M., Nozaki A., Sugiyama K., Tanaka T., Naganuma A., Tanaka K., Sekihara H., Shimotohno K., Saito M., and Kato N. Characterization of antiviral activity of lactoferrin against hepatitis C virus infection in human cultured cells. Virus Res. 66 1 (2000) 51-63
45. Isamida T., Tanaka T., Omata Y., Yamauchi K., Shimazaki K., and Saito A. Protective effect of lactoferricin against Toxoplasma gondii infection in mice. J. Vet. Med. Sci. 60 2 (1998) 241-244
46. Jenssen H. Anti herpes simplex virus activity of lactoferrin/lactoferricin-an example of antiviral activity of antimicrobial protein/peptide. Cell. Mol. Life Sci. 62 24 (2005) 3002-3013
47. Jenssen H., Andersen J.H., Mantzilas D., and Gutteberg T.J. A wide range of medium-sized, highly cationic, alpha-helical peptides show antiviral activity against herpes simplex virus. Antiviral Res. 64 2 (2004) 119-126
48. Jenssen H., Andersen J.H., Uhlin-Hansen L., Gutteberg T.J., and Rekdal O. Anti-HSV activity of lactoferricin analogues is only partly related to their affinity for heparan sulfate. Antiviral Res. 61 2 (2004) 101-109
49. Jing W., Svendsen J.S., and Vogel H.J. Comparison of NMR structures and model-membrane interactions of 15-residue antimicrobial peptides derived from bovine lactoferricin. Biochem. Cell Biol. 84 3 (2006) 312-326
50. Joyce J.G., Tung J.S., Przysiecki C.T., Cook J.C., Lehman E.D., Sands J.A., Jansen K.U., and Keller P.M. The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J. Biol. Chem. 274 9 (1999) 5810-5822
51. Kuwata H., Yip T.T., Yamauchi K., Teraguchi S., Hayasawa H., Tomita M., and Hutchens T.W. The survival of ingested lactoferrin in the gastrointestinal tract of adult mice. Biochem. J. 334 Pt 2 (1998) 321-323
52. Lin T.Y., Chu C., and Chiu C.H. Lactoferrin inhibits enterovirus 71 infection of human embryonal rhabdomyosarcoma cells in vitro. J. Infect. Dis. 186 8 (2002) 1161-1164
53. Longhi G., Pietropaolo V., Mischitelli M., Longhi C., Conte M.P., Marchetti M., Tinari A., Valenti P., Degener A.M., Seganti L., and Superti F. Lactoferrin inhibits early steps of human BK polyomavirus infection. Antiviral Res. 72 2 (2006) 145-152
54. Marchetti M., Longhi C., Conte M.P., Pisani S., Valenti P., and Seganti L. Lactoferrin inhibits herpes simplex virus type 1 adsorption to Vero cells. Antiviral Res. 29 2-3 (1996) 221-231
55. Marchetti M., Superti F., Ammendolia M.G., Rossi P., Valenti P., and Seganti L. Inhibition of poliovirus type 1 infection by iron-, manganese- and zinc-saturated lactoferrin. Med. Microbiol. Immunol. (Berl) 187 4 (1999) 199-204
56. Marchetti M., Trybala E., Superti F., Johansson M., and Bergstrom T. Inhibition of herpes simplex virus infection by lactoferrin is dependent on interference with the virus binding to glycosaminoglycans. Virology 318 1 (2004) 405-413
57. Mason D.Y., and Taylor C.R. Distribution of transferrin, ferritin, and lactoferrin in human tissues. J. Clin. Pathol. 31 4 (1978) 316-327
58. McCann K.B., Lee A., Wan J., Roginski H., and Coventry M.J. The effect of bovine lactoferrin and lactoferricin B on the ability of feline calicivirus (a norovirus surrogate) and poliovirus to infect cell cultures. J. Appl. Microbiol. 95 5 (2003) 1026-1033
59. Pietrantoni A., Ammendolia M.G., Tinari A., Siciliano R., Valenti P., and Superti F. Bovine lactoferrin peptidic fragments involved in inhibition of Echovirus 6 in vitro infection. Antiviral Res. 69 2 (2006) 98-106
60. Roden R.B., Greenstone H.L., Kirnbauer R., Booy F.P., Jessie J., Lowy D.R., and Schiller J.T. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J. Virol. 70 9 (1996) 5875-5883
61. Scheinfeld N., and Lehman D.S. An evidence-based review of medical and surgical treatments of genital warts. Dermatol. Online J. 12 3 (2006) 5
62. Seganti L., Di Biase A.M., Rega B., De Giulio B., Nicoletti M., Antonini G., and Valenti P. Involvement of bovine lactoferrin moieties in the inhibition of herpes simplex virus type 1 infection. Int. J. Immunopathol. Pharmacol. 14 2 (2001) 71-79
63. Shafti-Keramat S., Handisurya A., Kriehuber E., Meneguzzi G., Slupetzky K., and Kirnbauer R. Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses. J. Virol. 77 24 (2003) 13125-13135
64. Snoeck R. Papillomavirus and treatment. Antiviral Res. 71 2-3 (2006) 181-191
65. Spillmann D. Heparan sulfate: anchor for viral intruders?. Biochimie 83 8 (2001) 811-817
66. Strom M.B., Rekdal O., and Svendsen J.S. Antibacterial activity of 15-residue lactoferricin derivatives. J. Pept. Res. 56 5 (2000) 265-274
67. Stubenrauch F., and Laimins L.A. Human papillomavirus life cycle: active and latent phases. Semin. Cancer Biol. 9 6 (1999) 379-386
68. Superti F., Ammendolia M.G., Valenti P., and Seganti L. Antirotaviral activity of milk proteins: lactoferrin prevents rotavirus infection in the enterocyte-like cell line HT-29. Med. Microbiol. Immunol. (Berl) 186 2-3 (1997) 83-91
69. Swart P.J., Kuipers M.E., Smit C., Pauwels R., deBethune M.P., de Clercq E., Meijer D.K., and Huisman J.G. Antiviral effects of milk proteins: acylation results in polyanionic compounds with potent activity against human immunodeficiency virus types 1 and 2 in vitro. AIDS Res. Hum. Retroviruses 12 9 (1996) 769-775
70. Tuccari G., Giuffre G., Scarf R., Simone A., Todaro P., and Barresi G. Immunolocalization of lactoferrin in surgically resected pigmented skin lesions. Eur. J. Histochem. 49 1 (2005) 33-38
71. Unckell F., Streeck R.E., and Sapp M. Generation and neutralization of pseudovirions of human papillomavirus type 33. J. Virol. 71 4 (1997) 2934-2939
72. van Berkel P.H., Geerts M.E., van Veen H.A., Mericskay M., de Boer H.A., and Nuijens J.H. N-terminal stretch Arg2, Arg3, Arg4 and Arg5 of human lactoferrin is essential for binding to heparin, bacterial lipopolysaccharide, human lysozyme and DNA. Biochem. J. 328 Pt 1 (1997) 145-151
73. Vorland L.H., Ulvatne H., Andersen J., Haukland H.H., Rekdal O., Svendsen J.S., and Gutteberg T.J. Antibacterial effects of lactoferricin B. Scand. J. Infect. Dis. 31 2 (1999) 179-184
74. Weng T.Y., Chen L.C., Shyu H.W., Chen S.H., Wang J.R., Yu C.K., Lei H.Y., and Yeh T.M. Lactoferrin inhibits enterovirus 71 infection by binding to VP1 protein and host cells. Antiviral Res. 67 1 (2005) 31-37
75. Yi M., Kaneko S., Yu D.Y., and Murakami S. Hepatitis C virus envelope proteins bind lactoferrin. J. Virol. 71 8 (1997) 5997-6002
76. Yoo Y.C., Watanabe S., Watanabe R., Hata K., Shimazaki K., and Azuma I. Bovine lactoferrin and lactoferricin, a peptide derived from bovine lactoferrin, inhibit tumor metastasis in mice. Jpn. J. Cancer Res. 88 2 (1997) 184-190
77. Zhao K.N., Sun X.Y., Frazer I.H., and Zhou J. DNA packaging by L1 and L2 capsid proteins of bovine papillomavirus type 1. Virology 243 2 (1998) 482-491
78. Zhou J., Sun X.Y., Davies H., Crawford L., Park D., and Frazer I.H. Definition of linear antigenic regions of the HPV16 L1 capsid protein using synthetic virion-like particles. Virology 189 2 (1992) 592-599